← Back
Data updated: Mar 10, 2026
EXELIXIS
OncologyMetabolicGastroenterology
EXELIXIS is a pharmaceutical company focused on Oncology, Metabolic, Gastroenterology. Key products include CABOMETYX.
2012
Since
2
Drugs
-
Trials
4
Approved (2yr)
Key Drugs
Recent Activity
COMETRIQ 2025-10-09
Labeling
CABOMETYX 2025-10-09
Labeling
CABOMETYX 2025-09-10
Efficacy
CABOMETYX 2025-03-26
Efficacy
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 77%
1 drugs Phase 3: 6 Phase 2: 2 Phase 1: 13
Metabolic 20%
1 drugs Phase 3: 1 Phase 1: 2
Gastroenterology 3%
0 drugs Phase 1: 2
Pipeline Strength Pro
Loading...